Does Rallies track congressional trades in BSX?

Yes. Rallies tracks politician and congressional stock disclosures for BSX, including reported purchases, sales, dates, owners, and trade amounts when available.

Is BSX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BSX. It does not provide personalized investment advice.

BSX (Boston Scientific) Stock Analysis - Politician Trades

Boston Scientific (BSX) is a publicly traded Healthcare sector company. As of May 20, 2026, BSX trades at $56.63 with a market cap of $83.12B and a P/E ratio of 23.46. BSX moved -0.42% today. Year to date, BSX is -40.65%; over the trailing twelve months it is -46.81%. Its 52-week range spans $52.52 to $109.50. Analyst consensus is strong buy with an average price target of $89.12. Rallies surfaces BSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded BSX stock?

Recent politician trading activity in BSX includes disclosures from Ro Khanna, Michael McCaul, Gilbert Cisneros, Gilbert Cisneros, and Markwayne Mullin. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

BSX Key Metrics

Key financial metrics for BSX
Metric	Value
Price	$56.63
Market Cap	$83.12B
P/E Ratio	23.46
EPS	$2.41
Dividend Yield	0.00%
52-Week High	$109.50
52-Week Low	$52.52
Volume	12.02M
Avg Volume	0
Revenue (TTM)	$20.61B
Net Income	$3.56B
Gross Margin	69.17%

Congressional Trades in BSX

Ro Khanna purchase BSX on Mar 30, 2026 (amount: $50.00K).
Michael McCaul purchase BSX on Mar 27, 2026 (amount: $15.00K) for Spouse.
Gilbert Cisneros purchase BSX on Feb 10, 2026 (amount: $15.00K).
Gilbert Cisneros purchase BSX on Jan 30, 2026 (amount: $15.00K).
Markwayne Mullin purchase BSX on Dec 29, 2025 (amount: $50.00K) for Joint.

Latest BSX News

Boston Scientific Coronary IVL Catheter Hits 93.3% Safety, 93.7% Effectiveness — May 19, 2026
Boston Scientific Invests $1.5B for 34% MiRus Stake with $3B TAVR Option — May 18, 2026
Boston Scientific Launches $2B Accelerated Buyback, Secures 30.4M Shares — May 18, 2026
Boston Scientific’s $1.5B Investment Secures 34% Stake and $3B Option in TAVR Valve — May 18, 2026
Penumbra’s Q1 Revenue Jumps 15.6% to $374.8 Million with $9.4M Acquisition Expense — May 6, 2026

Recent BSX Insider Trades

Mahoney Michael F sold 1.20K (~$112.87K) on Feb 2, 2026.
Mahoney Michael F sold 159.70K (~$14.93M) on Feb 2, 2026.
Butcher Arthur C sold 17.31K (~$1.76M) on Dec 1, 2025.

BSX Analyst Consensus

27 analysts cover BSX: 0 strong buy, 26 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.12.

Common questions about BSX

Which politicians traded BSX stock?: Recent politician trading activity in BSX includes disclosures from Ro Khanna, Michael McCaul, Gilbert Cisneros, Gilbert Cisneros, and Markwayne Mullin. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in BSX?: Yes. Rallies tracks politician and congressional stock disclosures for BSX, including reported purchases, sales, dates, owners, and trade amounts when available.
Is BSX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BSX. It does not provide personalized investment advice.